{"id":"ingenol-mebutate-perrigo","safety":{"commonSideEffects":[{"rate":"80-90","effect":"Application site erythema"},{"rate":"50-70","effect":"Application site pain"},{"rate":"40-60","effect":"Application site edema"},{"rate":"30-50","effect":"Application site erosion"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ingenol mebutate activates protein kinase C, leading to direct cytotoxic effects on keratinocytes and induction of an inflammatory response that recruits immune cells to eliminate abnormal cells. This dual mechanism of direct cell death and immune activation makes it effective for field treatment of actinic keratosis on sun-damaged skin.","oneSentence":"Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of precancerous lesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:10.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (field treatment on face, scalp, or trunk)"}]},"trialDetails":[{"nctId":"NCT02459795","phase":"PHASE3","title":"To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-05","conditions":"Actinic Keratosis","enrollment":469},{"nctId":"NCT02385318","phase":"PHASE3","title":"To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-02","conditions":"Actinic Keratosis","enrollment":519}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Perrigo product"],"phase":"phase_3","status":"active","brandName":"Ingenol Mebutate (Perrigo)","genericName":"Ingenol Mebutate (Perrigo)","companyName":"Padagis LLC","companyId":"padagis-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of precancerous lesions. Used for Actinic keratosis (field treatment on face, scalp, or trunk).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}